Latest Insider Transactions at Vertex Pharmaceuticals Inc (VRTX)
This section provides a real-time view of insider transactions for Vertex Pharmaceuticals Inc (VRTX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of VERTEX PHARMACEUTICALS INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of VERTEX PHARMACEUTICALS INC 's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 12
2025
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,437
+17.6%
|
-
|
|
Feb 12
2025
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
5,546
+11.46%
|
-
|
|
Feb 12
2025
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
19,015
+12.27%
|
-
|
|
Feb 12
2025
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
6,211
+7.48%
|
-
|
|
Feb 12
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,080
+14.74%
|
-
|
|
Feb 12
2025
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
7,903
+9.26%
|
-
|
|
Feb 12
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
6,211
+17.42%
|
-
|
|
Feb 12
2025
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,324
+9.91%
|
-
|
|
Feb 11
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Open market or private sale
|
Direct |
310
-0.48%
|
$142,290
$459.83 P/Share
|
|
Feb 11
2025
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
3,433
-17.37%
|
$1,575,747
$459.87 P/Share
|
|
Feb 11
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Open market or private sale
|
Direct |
1,747
-7.0%
|
$801,873
$459.83 P/Share
|
|
Feb 11
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Open market or private sale
|
Direct |
1,376
-12.15%
|
$631,584
$459.83 P/Share
|
|
Feb 10
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,143
-3.22%
|
$1,000,781
$467.98 P/Share
|
|
Feb 10
2025
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,649
-4.31%
|
$1,237,083
$467.98 P/Share
|
|
Feb 10
2025
|
Reshma Kewalramani CEO & President |
SELL
Payment of exercise price or tax liability
|
Direct |
8,300
-6.63%
|
$3,876,100
$467.98 P/Share
|
|
Feb 10
2025
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
SELL
Payment of exercise price or tax liability
|
Direct |
2,056
-2.83%
|
$960,152
$467.98 P/Share
|
|
Feb 10
2025
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,632
-7.63%
|
$762,144
$467.98 P/Share
|
|
Feb 10
2025
|
Carmen Bozic EVP and CMO |
SELL
Payment of exercise price or tax liability
|
Direct |
2,142
-5.43%
|
$1,000,314
$467.98 P/Share
|
|
Feb 10
2025
|
Stuart A Arbuckle EVP, COO |
SELL
Payment of exercise price or tax liability
|
Direct |
3,220
-4.43%
|
$1,503,740
$467.98 P/Share
|
|
Feb 10
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
SELL
Payment of exercise price or tax liability
|
Direct |
876
-3.39%
|
$409,092
$467.98 P/Share
|
|
Feb 10
2025
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,142
-4.73%
|
$1,000,314
$467.98 P/Share
|
|
Feb 10
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
591
-4.96%
|
$275,997
$467.98 P/Share
|
|
Feb 04
2025
|
Charles F Wagner Jr EVP & Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
17,376
+13.12%
|
-
|
|
Feb 04
2025
|
Amit Sachdev EVP Chief Patient & Ext Af Off |
BUY
Grant, award, or other acquisition
|
Direct |
15,324
+10.03%
|
-
|
|
Feb 04
2025
|
Ourania Tatsis EVP, Chief Reg. & Quality Off. |
BUY
Grant, award, or other acquisition
|
Direct |
17,376
+12.2%
|
-
|
|
Feb 04
2025
|
Carmen Bozic EVP and CMO |
BUY
Grant, award, or other acquisition
|
Direct |
16,190
+18.25%
|
-
|
|
Feb 04
2025
|
Reshma Kewalramani CEO & President |
BUY
Grant, award, or other acquisition
|
Direct |
49,446
+17.85%
|
-
|
|
Feb 04
2025
|
Jeffrey M Leiden Executive Chairman |
BUY
Grant, award, or other acquisition
|
Direct |
15,414
+37.76%
|
-
|
|
Feb 04
2025
|
Jonathan Biller EVP and Chief Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,744
+18.15%
|
-
|
|
Feb 04
2025
|
Edward Morrow Atkinson Iii EVP, Chief Technical Ops. Off. |
BUY
Grant, award, or other acquisition
|
Direct |
9,876
+17.53%
|
-
|
|
Feb 04
2025
|
Kristen Ambrose SVP & Chief Accounting Officer |
BUY
Grant, award, or other acquisition
|
Direct |
4,420
+16.89%
|
-
|
|
Feb 04
2025
|
Stuart A Arbuckle EVP, COO |
BUY
Grant, award, or other acquisition
|
Direct |
23,072
+14.46%
|
-
|
|
Feb 04
2025
|
David Altshuler EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
19,428
+19.0%
|
-
|
|
Nov 15
2024
|
David Altshuler EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
15
-0.06%
|
$7,170
$478.56 P/Share
|
|
Nov 11
2024
|
Charles F Wagner Jr EVP & Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
3,000
-6.36%
|
$1,554,000
$518.27 P/Share
|
|
Nov 08
2024
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
15,198
-16.71%
|
$7,826,970
$515.0 P/Share
|
|
Oct 02
2024
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Open market or private sale
|
Direct |
999
-5.66%
|
$460,539
$461.66 P/Share
|
|
Oct 01
2024
|
Jonathan Biller EVP and Chief Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
630
-3.45%
|
$293,580
$466.84 P/Share
|
|
Aug 30
2024
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
646
-12.71%
|
$323,000
$500.0 P/Share
|
|
Aug 30
2024
|
Sangeeta N. Bhatia Director |
BUY
Exercise of conversion of derivative security
|
Direct |
646
+11.28%
|
$98,192
$152.74 P/Share
|
|
Aug 30
2024
|
Jeffrey M Leiden Executive Chairman |
SELL
Open market or private sale
|
Direct |
3,784
-27.46%
|
$1,888,216
$499.0 P/Share
|
|
Aug 08
2024
|
Sangeeta N. Bhatia Director |
SELL
Open market or private sale
|
Direct |
1,292
-22.56%
|
$602,072
$466.29 P/Share
|
|
Aug 08
2024
|
Sangeeta N. Bhatia Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,292
+18.41%
|
$196,384
$152.74 P/Share
|
|
Aug 07
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-8.93%
|
$1,085,280
$476.75 P/Share
|
|
Aug 01
2024
|
Bruce I Sachs Director |
SELL
Open market or private sale
|
Direct |
5,295
-11.69%
|
$2,689,860
$508.0 P/Share
|
|
Aug 01
2024
|
Bruce I Sachs Director |
BUY
Exercise of conversion of derivative security
|
Direct |
5,295
+10.47%
|
$661,875
$125.71 P/Share
|
|
Jul 30
2024
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
15,202
-14.32%
|
$7,677,010
$505.0 P/Share
|
|
Jul 24
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-8.2%
|
$1,112,640
$488.46 P/Share
|
|
Jul 22
2024
|
Reshma Kewalramani CEO & President |
SELL
Open market or private sale
|
Direct |
15,202
-12.52%
|
$7,555,394
$497.0 P/Share
|
|
Jul 10
2024
|
Carmen Bozic EVP and CMO |
SELL
Open market or private sale
|
Direct |
2,280
-7.58%
|
$1,110,360
$487.34 P/Share
|